Atara Biotherapeutics Inc., a leader in T-cell immunotherapy, has announced a significant milestone in its ongoing regulatory review process. The company has set a Prescription Drug User Fee Act (PDUFA) target action date of January 10, 2026, for its biologics license application $(BLA.AU)$ for Tabelecleucel (tab-cel® or Ebvallo™), aimed at treating Post-Transplant Lymphoproliferative Disease (PTLD). This regulatory milestone is crucial, as the approval of the BLA would trigger a $40 million milestone payment from Pierre Fabre Laboratories, enhancing Atara's financial flexibility significantly. Additionally, Atara has transferred most operational activities related to tab-cel to Pierre Fabre Laboratories. The company is also evaluating strategic options, including potential acquisitions or mergers, following the resubmission of the tab-cel BLA.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.